Have you been diagnosed with Primary Sjogren's Syndrome?

Do you suffer from Dry Eye?

If 'yes' to both questions, you may be eligible to participate in a clinical trial of Lacripep™

Lacripep™ is a synthetic tear protein fragment that may restore health to dry eyes

For more information about the trial, please contact so-occerfstudies@uab.edu or 205-934-6734

Patients will be compensated for each completed visit.
About the Trial
The trial will last 8 weeks and include 5 visits

Patients will be provided with ophthalmic drops of Lacripep™ or placebo

Lacripep™ is a synthetic fragment of the natural tear protein 'lacritin'

In animal studies, Lacripep™ and lacritin restore basal tearing and eye health

A Lacripep™-like fragment and lacritin are also deficient in Sjogren's syndrome tears

This trial to assess the safety and effectiveness of Lacripep™ in dry eye has been reviewed by an Institutional Review Board (IRB)

The trial is restricted to patients with primary Sjogren's Syndrome dry eye

It is necessary that you stop treatment of Restasis or Xiidra two weeks before